Companion Diagnostics Markets: Forecasts to 2018 (Cancer, Cardiovascular and Blood, Metabolic, Infection, Neurological, Others)
|出版日期||內容資訊||英文 298 Pages
|搭配診斷市場 Companion Diagnostics Markets: Forecasts to 2018 (Cancer, Cardiovascular and Blood, Metabolic, Infection, Neurological, Others)|
|出版日期: 2014年08月08日||內容資訊: 英文 298 Pages||
The global companion diagnostic market is on the rise, and companion diagnostic development is becoming a primary area of focus for pharmaceutical developers. Many companion diagnostics are now successfully marketed, mainly in the cancer segment, with several of them part of a routine diagnostic and treatment plan.
This report tracks these developments and provides detailed examples of drug-test pairs. It also provides market estimation and forecast models for business planning.
There had been a slow market uptake of companion diagnostics because companion tests lacked FDA approval, which prevented pharmaceutical companies from promoting the diagnostic. But the realization that companion diagnostics can decrease costs by identifying the patient population that will most likely benefit from a therapy and ruling out those therapies not likely to be effective has made companion diagnostics important to the delivery of care.
This report, Companion Diagnostics Markets tracks these new developments and focuses on companion diagnostics in medicine in 2013 and 2014. The report provides product analysis for the five broad areas of medical companion diagnostics and market information:
Companion diagnostics have met with considerable challenges in penetrating the market, but are now rising to the forefront of pharmaceutical development and treatment, increasing the probability of clinical success by identifying patients with the presence of biomarkers or disease-specific therapeutic targets that can dramatically improve outcomes. Companion diagnostics and biomarkers provide insight into understanding disease processes and ways that medicines can work to counteract the disease.
The majority of competitive participation for companion diagnostics is in the United States and Europe. However, competition is steadily escalating in the United States and Europe, which is encouraging more participation in other areas such as Asia and Latin America. There are numerous companies in the market which include large multiproduct companies such as Roche and Abbott and small niche developers such as 20/20 GeneSystems.
Companies profiles in this report include:
The analysis presented in this report is based on data from a combination of company, government, industry, institutional and private sources. It includes information from extensive literature reviews and discussions with experts in the field, including microbiologists, pathologists, hospital authorities, reimbursement specialists, research scientists, business development managers and marketing managers.
All market data are based on factory sales to the end user and not retail pricing or reimbursement payments. Market data pertains to the world market at the manufacturers' level. The base year for data was 2013. Historical data was provided for the years 2011 through 2013, with forecast data provided for 2014 through 2018. Compound annual growth rates (CAGRs) are provided for the 2011-2013 and 2013-2018 periods for each segment covered. Basic competitor summaries are included in each segment. The forecasted market analysis for 2013-2018 was largely based on demographic trends, new developments, biomarker development, companion diagnostic deals, company performance trends, merger and acquisitions, and global expansion.